AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36947125 — intervention group
Group type: COMPARATOR
Intervention: Control condition (details not specified in the abstract).
Number of subjects: 60
Study 36947125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving community health workers' service provision.
Number of subjects: 60
Study 36947125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving family members' support.
Number of subjects: 60
Study 36947155 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia in super-obese parturients
Number of subjects: 494
Study 36947155 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia in morbidly obese parturients
Number of subjects: 494
Study 36947201 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 2-stage diagnostic classifier based on mutational profiles in 18 of 53 sequenced genes
Number of subjects: 1298
Study 36947201 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 2-stage diagnostic classifier based on variant allele frequencies (VAFs) in 10 genes
Number of subjects: 1298
Study 36947201 — intervention group
Group type: COMPARATOR
Intervention: Classifier-predicted diagnosis
Number of subjects: 1298
Study 36947263 — intervention group
Group type: EXPERIMENTAL
Intervention: VFRs fabricated on conventional models
Number of subjects: 36
Study 36947263 — intervention group
Group type: EXPERIMENTAL
Intervention: VFRs fabricated on FDM models
Number of subjects: 36
Study 36947263 — intervention group
Group type: EXPERIMENTAL
Intervention: VFRs fabricated on SLA models
Number of subjects: 36
Study 36947263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower VFRs
Number of subjects: 36
Study 36947263 — intervention group
Group type: EXPERIMENTAL
Intervention: SLA models
Number of subjects: 36
Study 36947263 — intervention group
Group type: COMPARATOR
Intervention: Surface roughness
Number of subjects: 36
Study 36947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLOTTP/SDP
Number of subjects: 201
Study 36947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLE
Number of subjects: 201
Study 36947322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium oxybate (LXB) during OLOTTP/SDP and OLE
Number of subjects: 201
Study 36947466 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 100
Study 36947466 — intervention group
Group type: COMPARATOR
Intervention: No caffeine
Number of subjects: 100
Study 36947489 — intervention group
Group type: EXPERIMENTAL
Intervention: micro intervention condition (immediate positive parenting feedback)
Number of subjects: 120
Study 36947489 — intervention group
Group type: COMPARATOR
Intervention: care-as-usual control condition
Number of subjects: 120
Study 36947521 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI/PGTA+GS (n = 105)
Number of subjects: 1317
Study 36947521 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI/PGTA+GS (n = 46)
Number of subjects: 1317
Study 36947521 — intervention group
Group type: COMPARATOR
Intervention: ICSI/PGTA (n = 1,212)
Number of subjects: 1317
Study 36947589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordi-tropin (somatropin, Novo Nordisk) at a mean dose of 0.045 (0.011) mg/kg/day
Number of subjects: 2377
Study 36947589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordi-tropin (somatropin, Novo Nordisk)
Number of subjects: 2377
Study 36947593 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO therapy targeting an evolutionarily conserved region at the start of the UBE3A gene
Number of subjects: 0
Study 36947713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Leucine (MET+LEU) treatment
Number of subjects: 0
Study 36947734 — intervention group
Group type: EXPERIMENTAL
Intervention: Naporafenib 200 mg twice a day plus trametinib 1 mg once daily
Number of subjects: 66
Study 36947734 — intervention group
Group type: EXPERIMENTAL
Intervention: Naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily
Number of subjects: 66
Study 36947969 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased energy intake (Oligo/Amen+Cal)
Number of subjects: 113
Study 36947969 — intervention group
Group type: COMPARATOR
Intervention: Oligo/Amen Control
Number of subjects: 113
Study 36947969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Oligo/Amen+Cal and Oligo/Amen Control)
Number of subjects: 113
Study 36947970 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate diastolic dysfunction
Number of subjects: 218
Study 36947970 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 218
Study 36947970 — intervention group
Group type: COMPARATOR
Intervention: Normal diastolic function
Number of subjects: 218
Study 36948246 — intervention group
Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) 600 mg twice a day
Number of subjects: 79
Study 36948246 — intervention group
Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) at recommended phase 2 dose
Number of subjects: 79
Study 36948246 — intervention group
Group type: EXPERIMENTAL
Intervention: D-1553 (garsorasib) in patients with brain metastasis
Number of subjects: 79
Study 36948325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-specific acupoints
Number of subjects: 47
Study 36948325 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression-specific acupoints
Number of subjects: 47
Study 36948372 — intervention group
Group type: EXPERIMENTAL
Intervention: NOV03 (perfluorohexyloctane) ophthalmic drop, 4 times daily for 8 weeks
Number of subjects: 620
Study 36948372 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic saline (0.6%), 4 times daily for 8 weeks
Number of subjects: 620
Study 36948372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NOV03 and saline
Number of subjects: 620
Study 36948424 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Colonoscopy
Number of subjects: 3523
Study 36948424 — intervention group
Group type: COMPARATOR
Intervention: Sequential HSgFOBT
Number of subjects: 3523
Study 36948424 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Screening Colonoscopy
Number of subjects: 3523
Study 36948488 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 489
Study 36948504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 35
Study 36948504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab salvage therapy
Number of subjects: 35
Study 36948505 — intervention group
Group type: EXPERIMENTAL
Intervention: PrCa VBIR (adenovirus vector and plasmid DNA expressing PSMA, PSA, PSCA) plus tremelimumab 80 mg and sasanlimab 300 mg (RP2D) in mCRPC
Number of subjects: 91
Study 36948505 — intervention group
Group type: EXPERIMENTAL
Intervention: PrCa VBIR plus tremelimumab 80 mg (Cohort 1B-BCR) in BCR
Number of subjects: 91
Study 36948505 — intervention group
Group type: EXPERIMENTAL
Intervention: PrCa VBIR plus tremelimumab 80 mg plus sasanlimab 130 mg (Cohort 5B-BCR) in BCR
Number of subjects: 91
Study 36948505 — intervention group
Group type: EXPERIMENTAL
Intervention: PrCa VBIR in mCRPC
Number of subjects: 91
Study 36948505 — intervention group
Group type: EXPERIMENTAL
Intervention: PrCa VBIR overall
Number of subjects: 91
Study 36948531 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive home visits by community health workers (CHWs)
Number of subjects: 5112
Study 36948531 — intervention group
Group type: COMPARATOR
Intervention: Passive site-based care by community health workers (CHWs)
Number of subjects: 5112
Study 36948547 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI cohort
Number of subjects: 148
Study 36948547 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 148
Study 36948565 — intervention group
Group type: EXPERIMENTAL
Intervention: NTDT-PRO questionnaire
Number of subjects: 145
Study 36948567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy components (mindful attention, decentring, values and committed action)
Number of subjects: 192
Study 36948568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ferric Carboxymaltose (10 mL, 50 mg Fe)
Number of subjects: 158
Study 36948568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 36948572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rhythm monitoring with implantable loop recorder
Number of subjects: 392
Study 36948576 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy to restore ethanolamine-metabolising capacity
Number of subjects: 0
Study 36948576 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Number of subjects: 0
Study 36948576 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal conditioned media
Number of subjects: 0
Study 36948733 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion-only PCI
Number of subjects: 1015
Study 36949116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 40
Study 36949116 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Number of subjects: 40
Study 36949116 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 40
Study 36949116 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 40
Study 36949116 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC and NIPPV
Number of subjects: 40
Study 36949155 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib monotherapy 10-200 mg once or twice daily
Number of subjects: 115
Study 36949248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront 150 mg
Number of subjects: 60
Study 36949248 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 60
Study 36949248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36949284 — intervention group
Group type: EXPERIMENTAL
Intervention: High-implementer group (mean of 2.2 additional interventions)
Number of subjects: 10150
Study 36949284 — intervention group
Group type: COMPARATOR
Intervention: Low-implementer group
Number of subjects: 10150
Study 36949412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of quadriceps rectus femoris (QRF) on admission and discharge using a Chieson model ECO2 ultrasound system.
Number of subjects: 157
Study 36949478 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 0
Study 36949478 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) + thoracic endovascular aortic repair (TEVAR)
Number of subjects: 0
Study 36949485 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) models at clinic and community levels
Number of subjects: 84
Study 36949485 — intervention group
Group type: EXPERIMENTAL
Intervention: Community distribution points (CDPs) for diabetes or hypertension
Number of subjects: 84
Study 36949485 — intervention group
Group type: COMPARATOR
Intervention: Control arm with primary care clinics providing diabetes and hypertension care services without RHMs
Number of subjects: 84
Study 36949505 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised six-week endurance exercise programme (2×90 min/week)
Number of subjects: 327
Study 36949505 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and exercise programme
Number of subjects: 327
Study 36949577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Number of subjects: 34
Study 36949577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36949579 — intervention group
Group type: EXPERIMENTAL
Intervention: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Number of subjects: 394
Study 36949579 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 394
Study 36949579 — intervention group
Group type: COMPARATOR
Intervention: Dyad combinations (three different gels)
Number of subjects: 394
Study 36949623 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of rifampin
Number of subjects: 6656
Study 36949623 — intervention group
Group type: COMPARATOR
Intervention: 9 months of isoniazid
Number of subjects: 6656
Study 36949846 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Group (twice-weekly group improvisational dance classes for 12 weeks)
Number of subjects: 111
Study 36949846 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Alone (same dance movement and auditory stimuli without social interaction)
Number of subjects: 111
Study 36949846 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Group (improvisational party games without movement)
Number of subjects: 111
Study 36949846 — intervention group
Group type: COMPARATOR
Intervention: Usual Care control
Number of subjects: 111
Study 36949896 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month short message service (SMS) intervention, messages sent two times per week, included SSB intake assessments, educational information, infographic URLs, and strategies.
Number of subjects: 357
Study 36949896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with higher income and education levels.
Number of subjects: 357
Study 36949896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with reduced intention to change SSB behaviors.
Number of subjects: 357
Study 36949896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with higher baseline SSB intake.
Number of subjects: 357
Study 36949953 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac
Number of subjects: 94
Study 36950217 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 4.5 mg/m² orally
Number of subjects: 11
Study 36950303 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor tenotomy of claw/hammer toes
Number of subjects: 66
Study 36950303 — intervention group
Group type: COMPARATOR
Intervention: Standard of care including orthosis and shoe offloading
Number of subjects: 66
Study 36950415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg
Number of subjects: 120
Study 36950415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group N
Number of subjects: 120
Study 36950415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group OW
Number of subjects: 120
Study 36950415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 1.5 mg/kg in Group O
Number of subjects: 120
Study 36950450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomecel-B (intramyocardial injections)
Number of subjects: 10
Study 36950857 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (calcium and multivitamins) post-gastrectomy
Number of subjects: 94
Study 36950857 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adherence to calcium and multivitamin supplementation
Number of subjects: 94
Study 36950857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative nutritional counseling
Number of subjects: 94
Study 36950929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (initial dose 100 mg, adjustable to 50 mg or 200 mg)
Number of subjects: 477
Study 36950929 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 477
Study 36951052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1070
Study 36951156 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azacitidine maintenance therapy
Number of subjects: 0
Study 36951156 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36951168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib with ribavirin
Number of subjects: 0
Study 36951168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib with ribavirin and decitabine
Number of subjects: 0
Study 36951196 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent inactivated influenza vaccine (aTIV)
Number of subjects: 85
Study 36951196 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (TIV)
Number of subjects: 85
Study 36951387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 0
Study 36951813 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless ventricular pacemaker
Number of subjects: 0
Study 36951813 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once daily
Number of subjects: 180
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg 3 times weekly
Number of subjects: 180
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg once weekly
Number of subjects: 180
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67
Number of subjects: 180
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone receptor
Number of subjects: 180
Study 36951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin and high-density lipoprotein cholesterol
Number of subjects: 180
Study 36951827 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 180
Study 36951834 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI plus FU/LV
Number of subjects: 178
Study 36951834 — intervention group
Group type: COMPARATOR
Intervention: FU/LV alone
Number of subjects: 178
Study 36951854 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld, illuminated optical magnifiers
Number of subjects: 29
Study 36951871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide autorefraction
Number of subjects: 473
Study 36951871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate retinoscopy
Number of subjects: 473
Study 36951871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent with 1% tropicamide
Number of subjects: 473
Study 36951871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean spherical equivalent with SureSight
Number of subjects: 473
Study 36951890 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor data during ILI events
Number of subjects: 2435
Study 36951890 — intervention group
Group type: COMPARATOR
Intervention: Care-seeking participants
Number of subjects: 2435
Study 36951890 — intervention group
Group type: COMPARATOR
Intervention: Participants with confirmed influenza infection
Number of subjects: 2435
Study 36951890 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlative analyses between wearable sensor data and patient-reported outcomes
Number of subjects: 2435
Study 36951893 — intervention group
Group type: EXPERIMENTAL
Intervention: BSA weighted left ventricular end-diastolic diameter (bLVEDD)
Number of subjects: 9474
Study 36951893 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter (LVEDD)
Number of subjects: 9474
Study 36951893 — intervention group
Group type: EXPERIMENTAL
Intervention: BSA
Number of subjects: 9474
Study 36951893 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDD
Number of subjects: 9474
Study 36951893 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical bLVEDD
Number of subjects: 9474
Study 36951958 — intervention group
Group type: EXPERIMENTAL
Intervention: CMVpp65-sensitized T cells (CMVpp65-VSTs)
Number of subjects: 67
Study 36951987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvodynia group (n = 151)
Number of subjects: 151
Study 36951987 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 106)
Number of subjects: 151
Study 36952010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive games integrated in the dreaMS app, played twice a week for 5 weeks
Number of subjects: 31
Study 36952010 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 31
Study 36952231 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (20 mg/day)
Number of subjects: 12
Study 36952231 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (40 mg/day)
Number of subjects: 12
Study 36952231 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg intravenously every 2 weeks) + Cabozantinib (60 mg/day)
Number of subjects: 12
Study 36952372 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ostomy leakage notification system
Number of subjects: 25
Study 36952468 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCS intervention
Number of subjects: 91
Study 36952472 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM survivors with incident headache/worsening headache intensity at 12 months post-CABM
Number of subjects: 284
Study 36952472 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM survivors with unfavourable disability outcome (GOS)
Number of subjects: 284
Study 36952472 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM survivors with incident headache/worsening headache since meningitis onset
Number of subjects: 284
Study 36952472 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM survivors with incident hearing impairment
Number of subjects: 284
Study 36952472 — intervention group
Group type: EXPERIMENTAL
Intervention: CABM impairments
Number of subjects: 284
Study 36952517 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (Self-Management for Amputee Rehabilitation using Technology) with weekly support sessions from a trained peer mentor for goal setting and action planning for six weeks.
Number of subjects: 0
Study 36952517 — intervention group
Group type: COMPARATOR
Intervention: Usual care with weekly social contacts for six weeks.
Number of subjects: 0
Study 36952634 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib + Abiraterone Acetate plus prednisone (niraparib + AAP)
Number of subjects: 670
Study 36952634 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Abiraterone Acetate (placebo + AAP)
Number of subjects: 670
Study 36958330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/high-sugar snack
Number of subjects: 0
Study 36958330 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/low-sugar snack
Number of subjects: 0
Study 36958364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab plus best supportive care (BSC)
Number of subjects: 202
Study 36958364 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 202
Study 36958364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab plus BSC
Number of subjects: 202